Shares of Aptose Biosciences, Inc. (NASDAQ:APTO) (TSE:APS) have received a consensus recommendation of “Buy” from the seven brokerages that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $6.50.
A number of research analysts recently commented on the company. HC Wainwright raised Aptose Biosciences from a “neutral” rating to a “buy” rating and boosted their price target for the company from $1.00 to $4.00 in a research note on Thursday, September 7th. ValuEngine cut Aptose Biosciences from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Finally, Zacks Investment Research upgraded Aptose Biosciences from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a research report on Monday, August 14th.
Shares of Aptose Biosciences (APTO) opened at 1.44 on Thursday. The company’s market cap is $34.60 million. The stock has a 50 day moving average of $1.49 and a 200 day moving average of $1.28. Aptose Biosciences has a 12-month low of $0.78 and a 12-month high of $2.60.
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last posted its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.11) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.07. On average, equities analysts expect that Aptose Biosciences will post ($1.05) earnings per share for the current fiscal year.
About Aptose Biosciences
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
What are top analysts saying about Aptose Biosciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aptose Biosciences Inc. and related companies.